1. Patel P, Shah J. Safety and toxicological considerations of nanomedicines: the future directions. Current Clinical Pharmacology 2017; 12(2):73-82.

2. Mishra M, Prasad K, Ramakrishn S, Jha AK. Nanomaterials in drug delivery—Promises and limitations. Nano and Medical Materials 2024; 4(1).

3. Zhao L, Zhu Y, Chen Z, Xu H, Zhou J, Tang S, et al. Cardiopulmonary effects induced by occupational exposure to titanium dioxide nanoparticles. Nanotoxicology 2018; 12(2):169-184.

4. Babaei V, Ashtarinezhad A, Torshabi M, Teimourian S, Shahmirzaie M, Abolghasemi J, et al. Evaluating Inflammatory Gene Expression Linked to Chronic Obstructive Pulmonary Disease in Workers of the Nanoparticle Industries: A Cross‐Sectional Study. Health Science Reports 2026; 9(5):e72141.

5. Luo X, Xie D, Hu J, Su J, Xue Z. Oxidative stress and inflammatory biomarkers for populations with occupational exposure to nanomaterials: a systematic review and meta-analysis. Antioxidants 2022; 11(11):2182.

6. Mehrparvar N, Ashtarinezhad A, Shekaftik SO, Moghadasi N, Mohammadi S, Moosavi MS, et al. Occupational Exposure to UPVC Powder Containing Calcium Carbonate (CaCO3) Nanoparticles: A Cross‐Sectional Biological Monitoring and Qualitative Risk Assessment. Health Science Reports 2026; 9(5):e72182.

7. Jain K, Kumar Mehra N, K Jain N. Nanotechnology in drug delivery: safety and toxicity issues. Current pharmaceutical design 2015; 21(29):4252-4261.

8. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: nanotechnology, biology and medicine 2013; 9(1):1-14.

9. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery 2019; 18(6):463-477.

10. Martin O. Artificial intelligence in drug discovery and development. Advanced Sciences 2021; 3(2):1-10.